Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER-Medicare population-based study

Wiley & Sons·Feb 9

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research suggests that CDK4/6 inhibitors may be associated with overall survival in patients with HR+/HER2– metastatic breast cancer. The effectiveness of these inhibitors may vary depending on certain factors, such as HER2 status or molecular characteristics like BRCA-associated breast cancer. Adverse event profiles and toxicities are also being studied in relation to CDK4/6 inhibitor treatment in metastatic breast cancer.

Full coverage

Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer

The ASCO Post·May 29

HER2-Low Status Linked to Shorter PFS With First-Line CDK4/6 Inhibitors in HR-Positive Metastatic Breast Cancer

Oncodaily·Jun 21

Remarkable response to CDK4/6 inhibitor–based endocrine therapy in HR+/HER2− metastatic male breast cancer with visceral crisis: a case report

Frontiers·Dec 10

Molecular characteristics and prognostic insights into BRCA -associated breast cancer in Kazakhstan

Nature·Jan 17

Adverse Event Profiles Associated with CDK4/6 Inhibitors

Pharmacy Times·Oct 2

BRCA2-Driven Breast Cancer May Follow A Different Resistance Path On CDK4/6 Inhibitors

Oncodaily·Mar 16

105 Real-World Overall Survival With Palbociclib Plus an Aromatase Inhibitor (AI) in Overweight/Obese Patients With HR+/HER2− Metastatic Breast Cancer (MBC)

CancerNetwork·2d ago

Monitoring and Managing Toxicities of Cell Cycle Inhibitors in Metastatic Breast Cancer

ASCO Daily News·Apr 24

View original report at Wiley & Sons ↗

Fetching the latest headlines…